

DAFTAR PUSTAKA

- Al Amin, M. (2017). Klasifikasi Umur Manusia Berdasarkan Analisis Dimensi Fraktal *Box Counting* Dari Citra Wajah Dengan Deteksi Tepi Canny. MATHunesa (Jurnal Ilmiah Matematika), 2 (6).
- American Diabetes Association. (2021). Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. *Diabetes Care*, 44, S15–S33. <https://doi.org/10.2337/dc21-S002>
- Artasensi, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2020). Type 2 diabetes mellitus: A review of multi-target drugs. In *Molecules* (Vol. 25, Issue 8). MDPI AG. <https://doi.org/10.3390/molecules25081987>
- AssayGenie,.(2022).<https://www.assaygenie.com/human-synaptopodin-synpo-elisa-kit/>. Diakses 21 Mei 2022.
- Banday, M. Z., Sameer, A. S., & Nissar, S. (2020). Pathophysiology of diabetes: An overview. *Avicenna Journal of Medicine*, 10(04), 174–188. https://doi.org/10.4103/ajm.ajm_53_20
- Berbudi, A., Rahmadika, N., Tjahjadi, A. I., & Ruslami, R. (2019). Type 2 Diabetes and its Impact on the Immune System. *Current Diabetes Reviews*, 16(5), 442–449. <https://doi.org/10.2174/1573399815666191024085838>
- Bokenkamp, A. (2020). Proteinuria- Take a closer look!. *Pediatric Nephrology*: 35:533-541
- Chen. Z et al. (2019). Study on clinical value of urinary synaptopodin in diabetic nephropathy. *Chinese Journal of Practical Internal Medicine* ; (12): 551-553
- Christensen, I.E., Nielsen, R., Birn, H. (2013). Renal filtration, transport and metabolism of albumin and albuminuria. Seldin and Giebisch's *The Kidney*, Fifth Edition.
- Decroli, E. 2019. *Diabetes Melitus Tipe 2*. Pusat Penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Andalas: Padang
- Deller. T., Martin. K., Sophie. C., Alexander. D., Herbert. S., Giulia, G. S., Aime. Z., Karin. S., Tobias. B., Rol. Z., Michael. F., Peter. M. (2003). *Synaptopodin-deficient mice lack a spine apparatus and show deficits in synaptic plasticity*. PNAS Office. Vol.100. No. 18

- Deller, T, et al. (2006). A role for synaptopodin and the spine appartusin hippocampal synaptic plasticity. *Annals Of Anatomy, Science Direct*. Vol. 189. No. 5-16
- Do Nascimento, J F., Canani, L. H., Gerchman, F., Rodrigues, P.G., Joelsons, G., Dos Santos, M., et al., (2013). *Messenger RNA Levels of Podocyte-Associated Proteins in Subject With Different Degree of Glucose Tolerance With or Without Nephropathy*. *BMC Nephrology*, 14 (1), 1-10
- Ertana, J. Restada. (2016). Hubungan Lama Menderita dan Komplikasi Diabetes Mellitus Dengan Kualitas Hidup Pada Penderita Diabtes Melitus di Wilayah Puskesmas Gatak Sukoharjo. Universitas Muhammadiyah Surakarta
- Faselis, C., Katsimardou, A., Imprialos, K., Deligkaris, P., Kallistratos, M., & Dimitriadis, K. (2019). Microvascular Complications of Type 2 Diabetes Mellitus. *Current Vascular Pharmacology*, 18(2), 117–124. <https://doi.org/10.2174/1570161117666190502103733>
- Feng, D. (2020). Phosphorylstion of ky podocyte proteins and the association with proteinuric kidney disease. *America journal of physiologi. Renal physiology*, 319 (2).
- Flyvbjerg, A. (2017). The role of the complement system in diabetic nephropathy. *Nature Reviews Nephrology*, 13(5), 311–318. <https://doi.org/10.1038/nrneph.2017.31>
- Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020). Pathophysiology of type 2 diabetes mellitus. In *International Journal of Molecular Sciences* (Vol. 21, Issue 17, pp. 1–34). MDPI AG. <https://doi.org/10.3390/ijms21176275>
- Gang, Wang et al. (2007). Messenger RNA expression of podocyte-associated molecules in the urinary sediment of patients with diabeteic nephropathy. *Nphron Clin Pract*.
- Gluhovschi, C., Gluhovschi, G., Petrica, L., Timar, R., Velcirov, S., Ionita, I., Kaycsa, A., & Timar, B. (2016). Urinary biomarkers in the assessment of early diabetic nephropathy. *Journal of Diabetes Research*, 2016. <https://doi.org/10.1155/2016/4626125>
- Hara, M., Yamagata, K., Tomino, Y., Saito, A., Hirayama, Y., Ogasawara, S., Kurosawa, H., Sekine, S., & Yan, K. (2012). Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes:

Establishment of a highly sensitive ELISA to detect urinary podocalyxin. *Diabetologia*, 55(11), 2913–2919. <https://doi.org/10.1007/s00125-012-2661-7>

Harreiter, J., & Roden, M. (2019). Diabetes mellitus—Definition, classification, diagnosis, screening and prevention (Update 2019). *Wiener Klinische Wochenschrift*, 131, 6–15. <https://doi.org/10.1007/s00508-019-1450-4>

<https://www.uniprot.org/> , Diakses 21 Mei 2022.

Johns, E. C., Denison, F. C., Norman, J. E., & Reynolds, R. M. (2018). Gestational Diabetes Mellitus: Mechanisms, Treatment, and Complications. *Trends in Endocrinology and Metabolism*, 29(11), 743–754. <https://doi.org/10.1016/j.tem.2018.09.004>

KDIGO. (2013). Clinical Practice Guideline for the Evaluation and Management of Chronic Kindey Disease. Journal Of The International Society Of Nepgrology. Vol. 3. Issue 1

Koch,A.E., Nakhoul.R., Nakhoul.F., Nakhoul.N. (2020). Autophagy in diabetic nephropathy : a review. International urology and nephrology.Springer Nature

Marshal S.M & Flyvbjerg. A. (2017). *Diabetic Nephropathy*. In R.G. Holt, C. Cockram, A. Lyvbjerg, B. J. Goldstein, *Textbook of Diabetes* (FIFTH EDITION), Wiley Blackwell: 566-576

Mukherjee, B. (2018). *Diabetes and Obesity International Journal Podocyturia-A Reliable Marker for Early Diabetic Nephropathy Diabetes Obes Int J Podocyturia-A Reliable Marker for Early Diabetic Nephropathy*.

NIDDK. (2022). Albumin in urine. <https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/tests-diagnosis/albuminuria-albumin-urine>. Diakses pada 29 Juli 2022

Niken, W., Dwi, N. Ahsani. (2020). *Corellation Age, Duration Of Diabetes Mellitus, HbA1c Levels, and Erectile Dysfunction in Type II Diabetes Mellitus*. *Advances in Health Sciences Research*, Vol 33. Atlantis Press.

Ning, L., Suleiman, H. Y., & Miner, J. H. (2020). *Synaptopodin is dispensable for normal podocyte homeostasis but is protective in the context of acute podocyte injury*. *Journal of the American Society of Nephrology*, 31(12), 2815–2832.

<https://doi.org/10.1681/ASN.2020050572>

Ning, L., Suleiman, H. Y., & Miner, J. H. (2021). *Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome*. *American Journal of Physiology - Renal Physiology*, 321(1), F12–F25. <https://doi.org/10.1152/AJPRENAL.00035.2021>

Papadopoulou-Marketou, N., Kanaka-Gantenbein, C., Marketos, N., Chrousos, G. P., & Papassotiriou, I. (2017a). *Biomarkers of diabetic nephropathy: A 2017 update*. *Critical Reviews in Clinical Laboratory Sciences*, 54(5), 326–342. <https://doi.org/10.1080/10408363.2017.1377682>

Parchwani, D.N. & Upadhyah, A.A. (2012). *Diabetic Nephropathy; Progression and Pathophysiology*. *Int J Med Sci Public Health*. 1 (2): 59-70

Politano, S. A., Colbert, G. B., & Hamiduzzaman, N. (2020). Nephrotic Syndrome. In *Primary Care - Clinics in Office Practice* (Vol. 47, Issue 4, pp. 597–613). W.B. Saunders. <https://doi.org/10.1016/j.pop.2020.08.002>

Prasad, M. R., Tikaria, R. (2022). *Microalbuminuria*. StatPearls Publishing

Punthakee, Z., Goldenberg, R., & Katz, P. (2018). Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome. *Canadian Journal of Diabetes*, 42, S10–S15. <https://doi.org/10.1016/j.jcjd.2017.10.003>

Pusat Data dan Informasi. (2018). *Hari Diabetes Sedunia*. Jakarta. Kementerian Kesehatan RI.

Pusat Data dan Informasi. (2020). *Tetap Produktif, Cegah, dan Atasi Diabetes Melitus*. Jakarta. Kementerian Kesehatan RI

Sakamoto, S., Putalun, W., Vimolmangkang, S., Phoolcharoen, W., Shoyama, Y., Tanaka, H., & Morimoto, S. (2018). Enzyme-linked immunosorbent assay for the quantitative/qualitative analysis of plant secondary metabolites. *Journal of Natural Medicines*, 72(1), 32–42. <https://doi.org/10.1007/s11418-017-1144-z>

Sanchez-Niño, M. D., Perez-Gomez, M. V., Valiño-Rivas, L., Torra, R., & Ortiz, A. (2019). Podocyturia: Why it may have added value in rare diseases. *Clinical Kidney Journal*, 12(1), 49–52. <https://doi.org/10.1093/ckj/sfy081>

- Sekulic, M., & Pichler Sekulic, S. (2013). A compendium of urinary biomarkers indicative of glomerular podocytopathy. In *Pathology Research International* (Vol. 2013). <https://doi.org/10.1155/2013/782395>
- Samsu, N. (2018). *Patogenesis Penyakit Ginjal Diabetik*. UB Press.Malang
- Samsu, N. (2021). Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. *Hindawai Biomed Research International* (Vol. 2021).
- Sloan, L. A. (2019). Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects. In *Journal of Diabetes* (Vol. 11, Issue 12, pp. 938–948). John Wiley and Sons Inc. <https://doi.org/10.1111/1753-0407.12969>
- Soelistijo SA, Lindarto D, Decroli E, Permana H, Sucipto KW, Kusnadi Y, et. al. (2021). *Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia 2021*. 46.
- Tung, C. W., Hsu, Y. C., Shih, Y. H., Chang, P. J., & Lin, C. L. (2018). Glomerular mesangial cell and podocyte injuries in diabetic nephropathy. *Nephrology*, 23, 32–37. <https://doi.org/10.1111/nep.13451>
- Tziomalos, K. & Athyros, V.G. (2015). Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis. *The Review of Diabetic Studies: RDS*. 12 (1-2): 110
- Umanath, K., & Lewis, J. B. (2018). Update on Diabetic Nephropathy: Core Curriculum 2018. *American Journal of Kidney Diseases*, 71(6), 884–895.
- Valaiyapathi, B., Gower, B., & Ashraf, A. P. (2019). Pathophysiology of Type 2 Diabetes in Children and Adolescents. *Current Diabetes Reviews*, 16(3), 220–229. <https://doi.org/10.2174/1573399814666180608074510>
- Wagrowska, M. D., Danielewics, M. (2007). Synaptopodin immunoexpression in steoid responsive abd steroid-resisten minimal change disease and focal segmental glomerulosclerosis. *Nefrologia*. Vol. 27. No. 6
- Wang, G., Lai, F. M. M., Lai, K. B., Chow, K. M., Li, K. T. P., & Szeto, C.

- C. (2007). Messenger RNA expression of podocyte-associated molecules in the urinary sediment of patients with diabetic nephropathy. *Nephron - Clinical Practice*, 106(4), 169–180. <https://doi.org/10.1159/000104428>
- Yap, K., Drakew, A., Smilovic, D., Rietsche, M., Paul, M. H., Vuksic, M., Del Turco, D., & Deller, T. (2020). The actin-modulating protein synaptopodin mediates long-term survival of dendritic spines. *eLife*, 9, 1–31. <https://doi.org/10.7554/eLife.62944>
- Yu, S. M. W., Nissaisorakarn, P., Husain, I., & Jim, B. (2018). Proteinuric kidney diseases: A podocyte's slit diaphragm and cytoskeleton approach. In *Frontiers in Medicine* (Vol. 5, Issue SEP). Frontiers Media S.A. <https://doi.org/10.3389/fmed.2018.00221>
- Zeng, L., & Szeto, C. C. (2021). Urinary podocyte markers in kidney diseases. In *Clinica Chimica Acta* (Vol. 523, pp. 315–324). Elsevier B.V. <https://doi.org/10.1016/j.cca.2021.10.017>
- Zhang, J., Liu, J., & Qin, X. (2018). Advances in early biomarkers of diabetic nephropathy. In *Revista da Associacao Medica Brasileira* (Vol. 64, Issue 1, pp. 85–92). Associacao Medica Brasileira. <https://doi.org/10.1590/1806-9282.64.01.85>
- Zhang, X. X., Kong, J., & Yun, K. (2020a). Prevalence of Diabetic Nephropathy among Patients with Type 2 Diabetes Mellitus in China: A Meta-Analysis of Observational Studies. *Journal of Diabetes Research*, 2020. <https://doi.org/10.1155/2020/2315607>
- Zheng, Y., Ley, S. H., & Hu, F. B. (2018). Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nature Reviews Endocrinology*, 14(2), 88–98. <https://doi.org/10.1038/nrendo.2017.151>

LAMPIRAN

Curriculum Vitae (CV)

Data Pribadi

Nama Lengkap : Afni Juhairia Laisouw
TTL : Ambon, 30 April 1992
Jenis Kelamin : Perempuan
Agama : Islam
Email : ria.laisow@gmail.com
Alamat : Jln. Air Kuning Lrg. Bambu Kuning Desa Batu Merah Kecamatan Sirimau Kota Ambon Prov. Maluku

Data Pendidikan

SD : SD Al-Hilal II Kota Ambon
SMP : SMP Neg. 14 Kota Ambon
SMA : SMA Neg. 11 Kota Ambon
Perguruan Tinggi : D-IV Univ. Muhammadiyah Semarang

Master tabel penelitian

No	Kode sampel	Jenis kelamin	Umur (Tahun)	Riwayat DM	Kadar Albumin Urin	Kadar Synaptopodin urin
1	2	P	66	DMT2	13	0.51
2	8	L	53	DMT2	41	0.41
3	19	L	60	DMT2	721	0.35
4	21	P	56	DMT2	3	0.25
5	22	P	61	DMT2	59	0.36
6	33	P	50	DMT2	456	0.73
7	37	L	37	DMT2	4	0.53
8	40	P	49	DMT2	47	0.35
9	42	P	63	DMT2	7	0.36
10	48	L	63	DMT2	135	0.32
11	50	P	56	DMT2	8023	0.65
12	53	L	51	DMT2	2010	0.57
13	61	P	63	DMT2	206	0.43
14	62	L	54	DMT2	21	0.37
15	66	P	39	DMT2	2	0.46
16	74	P	48	DMT2	12	0.97
17	75	P	57	DMT2	7	0.61
18	79	L	42	DMT2	747	0.95
19	80	P	53	DMT2	13	0.57
20	86	L	47	DMT2	260	0.62
21	92	L	61	DMT2	7	0.73
22	97	P	58	DMT2	11	0.42
23	99	L	39	DMT2	2	1.16
24	101	P	63	DMT2	376	0.82
25	103	L	62	DMT2	230	3.62
26	104	P	56	DMT2	42	0.44
27	105	P	58	DMT2	26	2.33
28	14	P	55	DMT2	75	0.31
29	45	L	65	DMT2	15	0.34
30	46	P	43	DMT2	1285	0.31
31	49	L	62	DMT2	2	0.22
32	52	P	52	DMT2	4	0.27
33	54	L	44	DMT2	6	0.22
34	72	P	45	DMT2	7	0.24
35	76	L	61	DMT2	19	0.23
36	83	P	63	DMT2	3	0.2
37	84	L	61	DMT2	33	0.5
38	88	P	46	DMT2	5	0.24
39	90	P	65	DMT2	22	0.17
40	91		67	DMT2	18	0.25
41	9	P	37	NON	14	0.29
42	10	P	31	NON	4	0.64
43	11	L	43	NON	5	0.3
44	12	P	35	NON	5	0.56
45	13	L	37	NON	10	0.29
46	15	L	39	NON	3	0.21
47	16	P	35	NON	4	0.3

48	18	P	34	NON	5	0.19
49	20	L	38	NON	6	0.22
50	29	L	35	NON	6	0.19
51	38	P	36	NON	8	0.15
52	55	P	33	NON	2	0.26
53	59	L	33	NON	2	0.39
54	63	L	34	NON	5	0.17
55	64	L	38	NON	2	0.16
56	68	L	34	NON	2	0.38
57	100	P	50	NON	4	0.31
58	110	L	36	NON	2	0.26
59	111	L	40	NON	5	0.14
60	112	L	41	NON	3	0.2

Case Processing Summary

	Riwayat	Cases					
		N	Valid Percent	N	Missing Percent	N	Total Percent
Albuminuria	Non DM	20	100.0%	0	0.0%	20	100.0%
	DMT2	40	100.0%	0	0.0%	40	100.0%

Descriptives

	Riwayat	Statistic		Std. Error	
Albuminuria	Non DM	Mean	4.85	.674	
		95% Confidence Interval for Mean	Lower Bound	3.44	
			Upper Bound	6.26	
		5% Trimmed Mean	4.50		
		Median	4.50		
		Variance	9.082		
		Std. Deviation	3.014		
		Minimum	2		
		Maximum	14		
		Range	12		
	Interquartile Range	4			
	Skewness	1.724	.512		
	Kurtosis	3.617	.992		
	DMT2	Mean	374.38	205.815	
		95% Confidence Interval for Mean	Lower Bound	-41.92	
			Upper Bound	790.67	
		5% Trimmed Mean	137.17		
		Median	20.00		
		Variance	1694389.574		
		Std. Deviation	1301.687		
Minimum		2			
Maximum		8023			
Range		8021			
Interquartile Range	181				
Skewness	5.523	.374			
Kurtosis	32.495	.733			

Tests of Normality

	Riwayat	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Albuminuria	Non DM	.230	20	.007	.820	20	.002
	DMT2	.387	40	.000	.301	40	.000

a. Lilliefors Significance Correction

Case Processing Summary

	Riwayat	Valid		Cases Missing		Total	
		N	Percent	N	Percent	N	Percent
Synaptopodin Urin	Non DM	20	100.0%	0	0.0%	20	100.0%
	DMT2	40	100.0%	0	0.0%	40	100.0%

Descriptives

	Riwayat		Statistic	Std. Error			
Synaptopodin Urin	Non DM	Mean	.2805	.02933			
		95% Confidence Interval for Mean	Lower Bound	.2191			
			Upper Bound	.3419			
		5% Trimmed Mean	.2683				
		Median	.2600				
		Variance	.017				
		Std. Deviation	.13117				
		Minimum	.14				
		Maximum	.64				
		Range	.50				
		Interquartile Range	.12				
		Skewness	1.553	.512			
		Kurtosis	2.392	.992			
		DMT2	DMT2	Mean	.5848	.09780	
				95% Confidence Interval for Mean	Lower Bound	.3869	
					Upper Bound	.7826	
5% Trimmed Mean	.4742						
Median	.4150						
Variance	.383						
Std. Deviation	.61853						
Minimum	.17						
Maximum	3.62						
Range	3.45						
Interquartile Range	.34						
Skewness	3.762			.374			
Kurtosis	16.066			.733			

Tests of Normality

	Riwayat	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Synaptopodin Urin	Non DM	.211	20	.020	.843	20	.004
	DMT2	.258	40	.000	.552	40	.000

a. Lilliefors Significance Correction

Case Processing Summary

	Valid kategori	Cases				Total Percent	
		Percent	N	Missing Percent	N		
Synaptopodin urine	Dengan Nefropati	17	100.0%	0	0.0%	17	100.0%
	Tanpa Nefropati	23	100.0%	0	0.0%	23	100.0%

Descriptives

	kategori		Statistic	Std. Error	
Synaptopodin urine	Dengan Nefropati	Mean	.6906	.18887	
		95% Confidence Interval for Mean	Lower Bound	.2902	
			Upper Bound	1.0910	
		5% Trimmed Mean	.5490		
		Median	.4400		
		Variance	.606		
		Std. Deviation	.77871		
		Minimum	.31		
		Maximum	3.62		
		Range	3.31		
	Interquartile Range	.34			
	Skewness	3.723	.550		
	Kurtosis	14.612	1.063		
	Tanpa Nefropati	Mean	.5065	.09828	
		95% Confidence Interval for Mean	Lower Bound	.3027	
			Upper Bound	.7103	
		5% Trimmed Mean	.4322		
		Median	.3600		
		Variance	.222		
		Std. Deviation	.47132		
Minimum		.17			
Maximum		2.33			
Range		2.16			
Interquartile Range	.33				
Skewness	2.959	.481			
Kurtosis	10.285	.935			

Tests of Normality

	kategori	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Synaptopodin urine	Dengan Nefropati	.316	17	.000	.474	17	.000
	Tanpa Nefropati	.239	23	.001	.649	23	.000

a. Lilliefors Significance Correction

Mann-Whitney Test

Ranks

	Riwayat	N	Mean Rank	Sum of Ranks
Albuminuria	Non DM	20	17.05	341.00
	DMT2	40	37.23	1489.00
	Total	60		

Test Statistics^a

Albuminuria

Mann-Whitney U	131.000
Wilcoxon W	341.000
Z	-4.228
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: Riwayat

Mann-Whitney Test

Ranks

	Riwayat	N	Mean Rank	Sum of Ranks
Synaptopodin Urin	Non DM	20	19.20	384.00
	DMT2	40	36.15	1446.00
	Total	60		

Test Statistics^a Synaptopodin Urin

Mann-Whitney U	174.000
Wilcoxon W	384.000
Z	-3.545
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: Riwayat

Mann-Whitney Test

Ranks

	Kategori	N	Mean Rank	Sum of Ranks
Synaptopodin urin	Dengan nefropati	17	24.15	410.50
	Tanpa Nefropati	23	17.80	409.50
	Total	40		

Test Statistics^a Synaptopodin urin

Mann-Whitney U	133.500
Wilcoxon W	409.500
Z	-1.697
Asymp. Sig. (2-tailed)	.090
Exact Sig. [2*(1-tailed Sig.)]	.090 ^b

a. Grouping Variable: Kategori

b. Not corrected for ties.

Correlations

		Albuminuria_ DM T2	Synaptopodin urin_DMT2
Spearman's rho	Albuminuria_DMT2	Correlation Coefficient	1.000
		Sig. (2-tailed)	.
		N	40
	Synaptopodin urin_DMT2	Correlation Coefficient	.314*
		Sig. (2-tailed)	.048
		N	40

*. Correlation is significant at the 0.05 level (2-tailed).


ROC Curve

Case Processing Summary

Kategori	Valid N (listwise)
Positive ^a	17
Negative	23

Larger values of the test result variable(s) indicate stronger evidence for a positive actual state.

a. The positive actual state is ND.



Diagonal segments are produced by ties.

Area Under the Curve

Test Result Variable(s): Synaptopodin urine

Area	Std. Error ^a	Asymptotic Sig. ^b	Asymptotic 95% Confidence Interval	
			Lower Bound	Upper Bound
.659	.086	.090	.490	.828

The test result variable(s):

Synaptopodin urine has at least one tie between the positive actual state group and the negative actual state group.

Statistics may be biased.

a. Under the nonparametric assumption

b. Null hypothesis: true area = 0.5

Titik Koordinat	Cut Off	Sensifitas	Spesifitas
14*	0.39*	0.647	0.565

Case Processing Summary

	Usia	Valid		Missing		Cases Total	
		N	Percent	N	Percent	N	Percent
Synaptopodin Urin (Subjek DMT2)	Masa dewasa akhir (36-45tahun)	7	100.0%	0	0.0%	7	100.0%
	Masa lansia awal (46-55tahun)	11	100.0%	0	0.0%	11	100.0%
	Masa lansia akhir (56-65tahun)	20	100.0%	0	0.0%	20	100.0%
	manula > 65	2	100.0%	0	0.0%	2	100.0%

Descriptives

	Usia	Statistic	Std. Error
		95% Confidence Interval for Mean	
		Lower Bound	.2145
		Upper Bound	.8912
		5% Trimmed Mean	.5376
		Median	.4600
		Variance	.134
		Std. Deviation	.36586
		Minimum	.22
		Maximum	1.16
		Range	.94

	Interquartile Range		.71	
	Skewness		.971	.794
	Kurtosis		-.551	1.587
Masa lansia awal (46-55tahun)	Mean		.4736	.06342
	95% Confidence Intervalfor Mean	Lower Bound	.3323	
		Upper Bound	.6149	
	5% Trimmed Mean		.4590	
	Median		.4100	
	Variance		.044	
	Std. Deviation		.21035	
	Minimum		.24	
	Maximum		.97	
	Range		.73	
	Interquartile Range		.26	
	Skewness		1.294	.661
	Kurtosis		2.120	1.279
Masa lansia akhir (56-65tahun)	Mean		.6675	.18680
	95% Confidence Intervalfor Mean	Lower Bound	.2765	
		Upper Bound	1.0585	
	5% Trimmed Mean		.5311	
	Median		.3900	
	Variance		.698	
	Std. Deviation		.83538	
	Minimum		.17	
	Maximum		3.62	
	Range		3.45	
	Interquartile Range		.37	
	Skewness		2.974	
	Kurtosis		8.907	.512
Manula > 65 tahun	Mean		.3800	.13000
	95% Confidence Intervalfor Mean	Lower Bound	-1.2718	
		Upper Bound	2.0318	
	5% Trimmed Mean		.	
	Median		.3800	
	Variance		.034	
	Std. Deviation		.18385	
	Minimum		.25	
	Maximum		.51	
	Range		.26	
	Interquartile Range		.	
	Skewness		.	.
	Kurtosis		.	.

Tests of Normality

	Usia	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Synaptopodin Urin (Subjek DMT2)	Masa dewasa akhir (36-45tahun)	.239	7	.200*	.862	7	.157
	Masa lansia awal (46-55 tahun)	.164	11	.200*	.887	11	.126
	Masa lansia akhir (56-65tahun)	.328	20	.000	.553	20	.000
	manula > 65 tahun	.260	2	.			

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

NPar Tests

Kruskal-Wallis Test

		Ranks		N	Mean Rank
	Usia				
Synaptopodin Urin	Masa dewasa akhir (36-45 tahun)	(7	21.00
	Masa lansia awal (46-55 tahun)			11	21.64
	Masa lansia akhir (56-65 tahun)			20	20.03
	manula > 65			2	17.25
	Total			40	

Test Statistics^{a,b}

Synaptopodin Urin

Kruskal-Wallis H	.305
df	3
Asymp. Sig.	.959

a. Kruskal Wallis Test

b. Grouping Variable: Usia

Case Processing Summary

		Valid		Missing		Cases	
		Percent	N	Percent	N	Total	
						Percent	
Synaptopodin Urin (Subjek DMT2)	Lama DM						
	Durasi Pendek (1-5 tahun)	19	100.0%	0	0.0%	19	100.0%
	Durasi sedang (6-10tahun)	7	100.0%	0	0.0%	7	100.0%
	Durasi panjang (> 10tahun)	14	100.0%	0	0.0%	14	100.0%

Descriptives

		Lama DM		Statistic	Std. Error
Synaptopodin Urin(Subjek DMT2)	Durasi Pendek (1-5 tahun)	Mean		.4400	.04685
		95% Confidence Interval for Mean	Lower Bound	.3416	
			Upper Bound	.5384	
		5% Trimmed Mean		.4239	
		Median		.4200	
		Variance		.042	
		Std. Deviation		.20421	
		Minimum		.20	
		Maximum		.97	
		Range		.77	
		Interquartile Range		.32	
		Skewness		.996	.524
		Kurtosis		.919	1.014
		Durasi sedang (6-10tahun)	Durasi sedang (6-10tahun)	Mean	
95% Confidence Interval for Mean	Lower Bound			.2627	
	Upper Bound			.8459	
5% Trimmed Mean				.5392	
Median				.5000	
Variance				.099	
Std. Deviation				.31527	
Minimum				.22	
Maximum				1.16	
Range				.94	
Interquartile Range				.39	
Skewness				1.288	.794
Kurtosis				1.761	1.587
Durasi panjang (> 10tahun)	Durasi panjang (> 10tahun)			Mean	
		95% Lower Bound		.2293	

Confidence Interval for Mean	Upper Bound	1.3635	
5% Trimmed Mean		.6744	
Median		.3850	
Variance		.965	
Std. Deviation		.98222	
Minimum		.17	
Maximum		3.62	
Range		3.45	
Interquartile Range		.56	
Skewness		2.369	.597
Kurtosis		5.319	1.154

Tests of Normality

	Lama DM	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Synaptopodin Urin(Subjek DMT2)	Durasi Pendek (1-5 tahun)	.120	19	.200*	.919	19	.107
	Durasi sedang (6-10tahun)	.194	7	.200*	.902	7	.345
	Durasi panjang (> 10tahun)	.295	14	.002	.633	14	.000

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Ranks

	Lama DM	N	Mean Rank
Synaptopodin Urin(Subjek DMT2)	Durasi Pendek (1-5 tahun)	19	19.34
	Durasi sedang (6-10 tahun)	7	22.86
	Durasi panjang (> 10 tahun)	14	20.89
	Total	40	

Test Statistics^{a,b}

	Synaptopodin Urin
Kruskal-Wallis H	.487
df	2
Asymp. Sig.	.784

a. Kruskal Wallis Test



b. Grouping Variable: Lama DM

REKOMENDASI PERSETUJUAN ETIK

Nomor : 655/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 27 Oktober 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22090520	No Sponsor Protokol	
Peneliti Utama	Afni Juhairia Laisouw	Sponsor	
Judul Peneliti	ANALISIS HUBUNGAN ALBUMINURIA DENGAN SYNAPTOPODIN URIN PADA PENDERITA DIABETES MELITUS TIPE 2 (DMT2)		
No Versi Protokol	2	Tanggal Versi	25 Oktober 2022
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 27 Oktober 2022 sampai 27 Oktober 2023	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan 	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

